55 results about "Folinic acid" patented technology

A composition and various formulations comprise preventative or therapeutic amounts of an epiandrosterone, analogue thereof or salt thereof, and/or a ubiquinone or salt thereof, and a pharmaceutically or veterinarily acceptable carrier or diluent. The composition and formulations are useful for treating bronchoconstriction, respiratory tract inflammation and allergies, asthma, and cancer. A method of treating diseases associated with low adenosine levels or adenosine depletion comprises administering folinic acid or a pharmaceutically acceptable salt hereof in a preventative or therapeutic amount, or an amount effective to treat adenosine depletion.

A method of treating a disorder by nasally administering methylcobalamin, with or without folinic acid. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dislexia, depth perception problems, color viewing problems, visual and auditory processing problems, light modulation problems, night vision problems; e) speech problems such as finding words, apraxia, and articulation problems, sleep regulation problems, eye or muscle movement problems; and f) chronic fatigue problems, digestion problems, sensitivity to chemicals, viral infection, inflammatory conditions such as rheumatoid arthritis, sciatica, and fibromyalgia, asthma, irritable bowel, colitis, tinnitus, migraines, nail biting, autoimmune problems. In some embodiments, the disorders that are particularly addressed are ADHD, anxiety, stress and chronic stress, and irritable bowel.

The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens. Dosages, dosing schedules, and ancillary treatments are described.

A method of treating a disorder by lollipop administering methylcobalamin, with or without folinic acid by direct delivery to the trigeminal nerve. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dyslexia, depth perception problems, color viewing problems, visual and auditory processing problems, light modulation problems, night vision problems; e) speech problems such as finding words, apraxia, and articulation problems, sleep regulation problems, eye or muscle movement problems; and f) chronic fatigue problems, digestion problems, sensitivity to chemicals, viral infection, inflammatory conditions such as rheumatoid arthritis, sciatica, and fibromyalgia, asthma, irritable bowel, colitis, tinnitus, migraines, nail biting, autoimmune problems. In some embodiments, the disorders that are particularly addressed are ADHD, anxiety, stress and chronic stress, and irritable bowel. A lollipop for treating a psychological or neuro-physiological disorder and method of making thereof.

Methods of treating gastric cancer and reducing the viability of gastric cancer cells by administering folinic acid, fluorouracil, and oxaliplatin to a subject, and applying an alternating electric field to a target region of the subject are provided. In some instances, chemotherapy such as XELOX, FOLFOX and individual components thereof are administered to a subject followed by applying an alternating electric field to the subject.

The invention provides a preparation method of medical left folinic acid sodium and an application in preparation of tumor treatment medicine, relating to a preparation method of the medical left folinic acid sodium in tumor treatment medicine preparation. Two preparation methods of the medical left folinic acid sodium are that: firstly, the left folinic acid sodium of prescription dosage are weighed, water for injection is added to prepare a suspension solution, sodium hydroxide solution (or sodium carbonate, sodium bicarbonate solution) is added, the suspension solution is stirred for total dissolution, and then at least one supplement containing mannitol, dextran, glucose, sodium chloride or protein hydrolysate is added; the injecting agents comprise the dried powder injection and the directly prepared liquid formulation. Secondly, the left folinic acid sodium of prescription dosage are weighed, water for injection is added, and at least one supplement containing mannitol, dextran, glucose, sodium chloride or protein hydrolysate are added and stirred for total dissolution to prepare the solution; the injecting agents comprise the dried powder and the directly prepared liquid formulation. The left folinic acid sodium is applied in preparing medicine of tumor treatment.

The invention relate to the sodium leucovorin injection and the preparing method. The sodium leucovorin injection contains sodium leucovorin and water for injection. The preparing method is to prepare sodium leucovorin solution through reaction with leucovorin and sodium-hydroxide solution, regulating the pH to 7.8-8.1 with sodium-hydroxide or chlorhydric acid to getting the half-finished product solution, filtering the half-finished product solution through double microporous filtering film (0.22ª–m), loading into bottle, sealing with rubber plug, the whole process is carried out in environment of filling with nitrogen. The property of the produced sodium leucovorin is stable, which is good for long term storage, there is little particle matter and chance for pollution, and the clinical effect is good.

The administration of levoleucovorin is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salt of levoleucovorin has a limited solubility in water and forms almost insoluble degradation products. Therefore aqueous solutions are unstable and precipitates are resulting. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions containing calcium salts, magnesium or zinc salts of levoleucovorin and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt are disclosed.

The present invention relates to a method for the treatment of cancer or an autoimmune disorder, comprising the administration of a serine hydroxymethyltransferase (SHMT) inhibitor, and in particular the administration of pyrazolopyran compounds of Formula (VI) as presently described, wherein the compounds are capable of inhibiting a mammalian SHMT, such as human SHMT1 and/or SHMT2. The treatment method further comprises the optional administration of an additional agent as a rescue therapy to reduce toxicity, wherein said agent may be chosen from formate, a formate salt, folinic acid, formate ester, or leucovorin.

A process for preparing levo-folinic acid and its calcium salt includes such steps as dissolving (6RS)-folinic acid and its calcium salt, chromatography with the adsorption column of neutral or alkaline adsorbent, eluting, collecting solution, regulating pH to 7.0, adding alcohol to educe out (6S)-folinic acid and its calcium salt, and recrystallizing in water 1-3 times. Its advantages are high purity (99% or more), high output and low cost.

The invention belongs to the field of medicaments for curing infantile brain development obstacle diseases and particularly relates to a medicament composition and application thereof. The medicament composition utilizes sharpleaf galangal fruit, lycium barbarum, fructus amomi, myristica fragrans and Chinese radish seed as raw materials, auxiliary materials including L-carnitine, taurine, zinc gluconate, folinic acid, vitamin B1, vitamin B2, vitamin B6, vitamin C, sodium ascorbate, potassium citrate and the like are added into supernate after water extraction of the raw materials to mix with the supernate, the mixture is evenly stirred, and then the mixture is filtered and filled to obtain the medicament composition. The medicament composition mostly adopts medicine edible ingredients andvitamin nutrition tonic ingredients and is free of toxic and side effect and clinically-proven effective in cure of the infantile brain development obstacle diseases through clinical prove.

The invention relates to a composite fluorouracil anti-tumor medicament, which consists of sodium folinate and fluorouracil, wherein the weight ratio of scalar-folinate of the sodium folinate to the fluorouracil is 1:(1-15), preferably 1:(1-5). A preparation is a freeze-dried injection or an injection. An auxiliary material of the preparation is one or more of mannitol, dextran, glucose, sodium hydroxide and sodium chloride. An experiment performed by Guangzhou Jiacheng Medical Science and Technology Co., Ltd. proves that composite fluorouracil can bring biological regulating effect of folinate into play better than alternate use of folinate and 5-FU, and tumor treatment is safer and more effective under the synergistic action of folinate and 5-FU. Under the condition of equal dosage, combined use of the folinate and 5-FU realizes longer tumor progress time, prolongs overall service life and lowers toxic or side reaction compared with alternate administration. Due to the reduction in toxicity, a large amount of 5-FU can be used clinically for achieving the effect of killing tumor cells.

It is intended to provide: an antitumor effect potentiator containing a therapeutically efficacious amount of Tegafur, Gimeracil in an amount efficacious for potentiating the antitumor effect and Oteracil potassium in an amount efficacious in inhibiting side effects, characterized by containing at least one component selected from the group consisting of folinic acid and its pharmaceutically acceptable salts in an amount efficacious for potentiating the antitumor effect as the active ingredient; an antitumor agent characterized by containing a therapeutically efficacious amount of Tegafur, Gimeracil in an amount efficacious for potentiating the antitumor effect and Oteracil potassium in an amount efficacious in inhibiting side effects and , together with at least one component selected from the group consisting of folinic acid and its pharmaceutically acceptable salts in an amount efficacious for potentiating the antitumor effect as the active ingredient; a method of potentiating the antitumor effect of an antitumor agent characterized by comprising administering the above-described antitumor effect potentiator to a patient; and a method of treating cancer characterized by comprising administering the above antitumor agent to a patient.

The present invention relates to a disinfection preparation containing levorotatory folinic acid sodium and a preparation method thereof. The levorotatory folinic acid sodium is a pharmaceutical composition, which is prepared from a main component of levorotatory folinic acid sodium and pharmaceutically acceptable excipients. The disinfection preparation has advantage that an injection disinfection preparation with high level of sterility assurance is prepared by addition of pharmaceutically acceptable stabilizer and inert gas protection and through terminal disinfection process.

The invention relates to a stable sodium folinate injection, which contains folinic acid or its pharmaceutically acceptable salt as an active ingredient and water for injection, and it also contains leucovorin or its pharmaceutically acceptable salt as an active ingredient The weight ratio is a stabilizer of 0.0001:1-5:1, and the pH value of the injection is adjusted to 6.5-8.5 by using a pH regulator. The present invention thereby enables stable formulations of sodium folinate in high concentrations in physiologically compatible isotonic solutions.

The invention provides a freeze-dried sterile injection powder containing an active component named levorotation folinic acid; the invention contains 9-100% levorotation folinic acid, 0-91% excipients acceptable in pharmacy or/and appropriate pH moderator. The pharmaceutical excipients refer to one or a plurality of mannitol, dextran, cane sugar, lactose, gelatin and phosphate. The pH moderator refers to one or a plurality of NaOH, natronite, kalium bicarbonicum, sodium phosphate, etc. The invention also relates to the preparation of the freeze-dried sterile injection powder. The invention avoids decomposition caused by high temperature sterilization in the process of levorotation folinic acid preparation, and is suitable for mass production; the invention is low in water content and stable when placed at room temperature, so the invention is suitable for long-term storage. The sterile injection powder of the invention can be taken as a synergist or attenuation agent in tumor chemotherapy.

The invention relates to a compound sodium levofolinate fluorouracil antineoplastic medicament which comprises sodium levofolinate and fluorouracil. The weight ratio of the scalar quantity-levofolinate of the sodium levofolinate to the fluorouracil is 1:(2-30), preferably 1:(2-10). A preparation is freezing and drying injection or injection. A preparation auxiliary material is one or more of mannitol, dextran, glucose, sodium hydroxide and sodium chloride. Proved by the JiaCheng medical technology limited company of Guangzhou through experiments, the compound sodium levofolinate fluorouracil can more favorably exert the biological regulating effect of levofolinate compared with the staggered use of sodium levofolinate and 5-FU and the treatment on tumors is safer and more effective by the cooperation of the sodium levofolinate and 5-FU. The matching use has longer tumor progression time compared with staggered medicament application under same dosage, prolongs the total life cycle and reduces the toxic or side reaction. The reduction of toxicity ensures that a large dose of 5-FU can be used in clinic so as to achieve the effect of killing tumor cells.

The invention relates to a pharmaceutical composition containing aspirin, clopidogrel and a folic acid compound. According to the pharmaceutical composition disclosed by the invention, the folic acid compound is prepared from the following components including folic acid, 5-methyltetrahydrofolic acid, formyl tetrahydrofolic acid, folinic acid, calcium levofolinate and medicinal salts of folic acid. The pharmaceutical composition is preferentially prepared from the following components by weight: 50-150mg of aspirin, 50-100mg of clopidogrel and 0.4-2mg of folic acid compound. The invention also relates to an application of the pharmaceutical composition in preparing a medicament for preventing a thromboembolic disease. With the adoption of the pharmaceutical composition, the medicament prepared from the pharmaceutical composition has a remarkable effect of inhibiting formation of thrombus on the basis of effectively inhibiting platelet aggregation; in addition, a patient is convenient to take the pharmaceutical composition, and compliance is improved.

The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens. Dosages, dosing schedules, and ancillary treatments are described.

The invention relates to a method for efficiently preparing low-calcium-content folinic acid. The method for efficiently preparing the low-calcium-content folinic acid comprises the following steps: dropwise adding a dissolved folinic acid aqueous solution and diluted hydrochloric acid with certain concentration into water, strictly controlling system temperature and pH value, separating out solids, washing, and drying, so that the low-calcium-content folinic acid is obtained. The obtained low-calcium-content folinic acid product is good in solid physical property and low in calcium content, and operation is easy, so that the method for efficiently preparing the low-calcium-content folinic acid is applicable to industrial production.

Aptamers that specifically bind to ligands of folinic acid, a folate, and derivatives thereof (which may be referred to herein as ligands) are provided, and compositions and methods of use thereof. The aptamers and switches of the invention provide biological sensing capability for detecting the ligands, and are effective in sensing in vitro and in vivo. By specific sensing of the ligand, the aptamers of the invention provide a means of engineering an inducible gene regulatory system that enables dose-dependent control over gene expression in response to the ligand, in vivo and in vitro.